| Phase 3 |
| NCT06735391 |
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as… |
Locally Advanced or Metastatic Non-squamous NSCLC |
Recruiting |
| NCT06846437 |
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer |
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants |
Recruiting |
| NCT06829459 |
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib… |
Non-Small Cell Lung Cancer |
Recruiting |
| NCT05838066 |
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of… |
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer |
Recruiting |
| NCT07441460 |
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable… |
Resectable HER2-positive Breast Cancer |
Recruiting |
| NCT05813665 |
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With… |
Giant Cell Tumor of Bone |
Not Yet Recruiting |
| NCT06221072 |
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases… |
Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors |
Not Yet Recruiting |
| NCT06380348 |
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With… |
Local Advanced or Metastatic NSCLC |
Not Yet Recruiting |
| NCT07134205 |
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic… |
Metastatic Colorectal Cancer (mCRC) |
Not Yet Recruiting |
| NCT07384377 |
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced… |
HER2-positive Colorectal Cancer |
Not Yet Recruiting |
| NCT06747338 |
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant… |
Early or Locally Advanced HER2-positive Breast Cancer |
Active, Not Recruiting |
| Phase 2/3 |
| NCT05427383 |
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have… |
Stomach Cancer |
Recruiting |
| NCT06319313 |
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous… |
Squamous Cell Non-small Cell Lung Cancer |
Not Yet Recruiting |
| NCT06908772 |
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients |
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression |
Not Yet Recruiting |
| NCT07332533 |
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer |
HER2-positive Gastric Cancer |
Not Yet Recruiting |
| Phase 2 |
| NCT06391944 |
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer… |
Local Advanced or Metastatic NSCLC |
Active, Not Recruiting |
| NCT06892431 |
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer |
Recurrent or Metastatic Nasopharyngeal Cancer |
Not Yet Recruiting |
| NCT06998771 |
JSKN003 Combined Treatment of HER2-positive Gastric Cancer |
HER2-positive Gastric Cancer |
Not Yet Recruiting |
| NCT07029139 |
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary… |
Primary Membranous Nephropathy |
Not Yet Recruiting |
| NCT07545044 |
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as… |
HER2-positive Recurrent or Metastatic Breast Cancer |
Not Yet Recruiting |
| Phase 1/2 |
| NCT07140809 |
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia |
Hypertriglyceridemia |
Recruiting |
| NCT07280832 |
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant… |
Unresectable Locally Advanced or Metastatic Melanoma |
Recruiting |
| NCT06877650 |
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant… |
Advanced Malignant Tumors |
Recruiting |
| NCT06868849 |
A Study of JMT203 in Patients With Cancer Cachexia |
Non Small Cell Lung Cancer |
Recruiting |
| NCT07472647 |
SYS6090 Combination Therapy in Advanced Lung Cancer |
Non-Small Cell Lung Cancer |
Not Yet Recruiting |